Version 1
: Received: 6 April 2022 / Approved: 8 April 2022 / Online: 8 April 2022 (03:27:23 CEST)
Version 2
: Received: 5 June 2022 / Approved: 6 June 2022 / Online: 6 June 2022 (05:53:21 CEST)
How to cite:
Ishikawa, T.; Kodama, E.; Kobayashi, T.; Azumi, M.; Nozawa, Y.; Iwanaga, A.; Sano, T.; Honma, T. Efficacy of Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma with Glass Membrane Emulsification Device. Preprints2022, 2022040069. https://doi.org/10.20944/preprints202204.0069.v1
Ishikawa, T.; Kodama, E.; Kobayashi, T.; Azumi, M.; Nozawa, Y.; Iwanaga, A.; Sano, T.; Honma, T. Efficacy of Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma with Glass Membrane Emulsification Device. Preprints 2022, 2022040069. https://doi.org/10.20944/preprints202204.0069.v1
Ishikawa, T.; Kodama, E.; Kobayashi, T.; Azumi, M.; Nozawa, Y.; Iwanaga, A.; Sano, T.; Honma, T. Efficacy of Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma with Glass Membrane Emulsification Device. Preprints2022, 2022040069. https://doi.org/10.20944/preprints202204.0069.v1
APA Style
Ishikawa, T., Kodama, E., Kobayashi, T., Azumi, M., Nozawa, Y., Iwanaga, A., Sano, T., & Honma, T. (2022). Efficacy of Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma with Glass Membrane Emulsification Device. Preprints. https://doi.org/10.20944/preprints202204.0069.v1
Chicago/Turabian Style
Ishikawa, T., Tomoe Sano and Terasu Honma. 2022 "Efficacy of Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma with Glass Membrane Emulsification Device" Preprints. https://doi.org/10.20944/preprints202204.0069.v1
Abstract
Background: Transarterial chemoembolization (TACE) is the standard treatment for BCLC-B hepatocellular carcinoma (HCC). The glass membrane emulsification device (GMD), a novel device, produces a high percentage of water/oil emulsions with homogeneous and stable droplets. There are few reports on the efficacy of GMD-conventional-TACE (GMD-c-TACE). We aimed to evaluate the efficacy of GMD-c-TACE. Methods: Seventy-one patients with HCC of tumor diameter <5 cm who underwent c-TACE with and without GMD were included in this study to investigate local recurrence and hepatic functional reserve. Results: Local recurrence rates without GMD-TACE was 3.0% at 6 months, 16.7% at 12 months, 35.0% at 18 months, and it then plateaued. Hence, the local recurrence rate in the GMD-c-TACE group was 7.7% at 14 months and 23.1% at 20 months, respectively. GMD-c-TACE had a significantly lower local recurrence. Multivariate analysis showed that GMD-c-TACE could suppress local recurrence and maintain the hepatic reserve. Conclusions: GMD-c-TACE allows dense accumulation of lipiodol in the tumor and attainment of good local control. Additionally, the inhibition of the release of anticancer drugs may maintain the hepatic reserve. GMD-c-TACE is useful in preventing local recurrence and is expected to become the standard treatment form of c-TACE in the future.
Medicine and Pharmacology, Gastroenterology and Hepatology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
